Oric Pharmaceuticals Inc To Review Initial Data ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-Paclitaxel Transcript - Thomson StreetEvents

Oric Pharmaceuticals Inc To Review Initial Data ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-Paclitaxel Transcript

Oric Pharmaceuticals Inc To Review Initial Data ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-Paclitaxel Transcript - Thomson StreetEvents
Oric Pharmaceuticals Inc To Review Initial Data ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-Paclitaxel Transcript
Published Jun 02, 2021
Published Jun 02, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ORIC.OQ conference call or presentation 2-Jun-21 9:00pm GMT

  
Report Type:

Transcript

Source:
Company:
Oric Pharmaceuticals Inc
Ticker
ORIC.OQ
Time
9:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Oric Pharmaceuticals Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript – 2022-02-10 – US$ 54.00 – Edited Transcript of ORIC.OQ presentation 10-Feb-22 7:00pm GMT

Oric Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2022-01-11 – US$ 54.00 – Edited Transcript of ORIC.OQ presentation 11-Jan-22 8:00pm GMT

Oric Pharmaceuticals Inc to Discuss CD73 Inhibitor Program in Multiple Myeloma Transcript – 2021-12-13 – US$ 54.00 – Edited Transcript of ORIC.OQ conference call or presentation 13-Dec-21 10:30pm GMT

Oric Pharmaceuticals Inc at AACR-NCI-EORTC Virtual International Conference Transcript – 2021-10-07 – US$ 54.00 – Edited Transcript of ORIC.OQ corporate analyst meeting</ 7-Oct-21 1:00pm GMT

Oric Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) Transcript – 2021-09-10 – US$ 54.00 – Edited Transcript of ORIC.OQ presentation 10-Sep-21 1:45pm GMT

Oric Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2021-01-12 – US$ 54.00 – Edited Transcript of ORIC.OQ presentation 12-Jan-21 8:40pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Oric Pharmaceuticals Inc To Review Initial Data ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-Paclitaxel Transcript" Jun 02, 2021. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Oric-Pharmaceuticals-Inc-To-Review-Initial-Data-ASCO-from-Phase-1b-Study-of-ORIC-101-in-Combination-with-Nab-Paclitaxel-T14824682>
  
APA:
Thomson StreetEvents. (2021). Oric Pharmaceuticals Inc To Review Initial Data ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-Paclitaxel Transcript Jun 02, 2021. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Oric-Pharmaceuticals-Inc-To-Review-Initial-Data-ASCO-from-Phase-1b-Study-of-ORIC-101-in-Combination-with-Nab-Paclitaxel-T14824682>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.